Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients. / Rapacki, Etienne; Lauritzen, Jes B.; Madsen, Christian M.; Jørgensen, Henrik L.; Norring-Agerskov, Debbie.

I: European Journal of Trauma and Emergency Surgery, Bind 47, 2021, s. 1081–1087.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rapacki, E, Lauritzen, JB, Madsen, CM, Jørgensen, HL & Norring-Agerskov, D 2021, 'Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients', European Journal of Trauma and Emergency Surgery, bind 47, s. 1081–1087. https://doi.org/10.1007/s00068-019-01260-9

APA

Rapacki, E., Lauritzen, J. B., Madsen, C. M., Jørgensen, H. L., & Norring-Agerskov, D. (2021). Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients. European Journal of Trauma and Emergency Surgery, 47, 1081–1087. https://doi.org/10.1007/s00068-019-01260-9

Vancouver

Rapacki E, Lauritzen JB, Madsen CM, Jørgensen HL, Norring-Agerskov D. Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients. European Journal of Trauma and Emergency Surgery. 2021;47:1081–1087. https://doi.org/10.1007/s00068-019-01260-9

Author

Rapacki, Etienne ; Lauritzen, Jes B. ; Madsen, Christian M. ; Jørgensen, Henrik L. ; Norring-Agerskov, Debbie. / Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients. I: European Journal of Trauma and Emergency Surgery. 2021 ; Bind 47. s. 1081–1087.

Bibtex

@article{848d11a8d0424704aaee4d1c66916c2e,
title = "Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients",
abstract = "Purpose: The aim of this study is to assess the possible association between thyroid-stimulating hormone (TSH) and mortality in hip fracture patients. Patients and methods: The study is based on a hip fracture database from Bispebjerg University Hospital (Copenhagen, Denmark). This database includes all hip fracture patients (ICD-10 codes DS720 (femoral neck), DS721 (pertrochanteric), and DS722 (subtrochanteric)) admitted to Bispebjerg Hospital from 1996 to 2012. From this database, we identified all surgically treated hip fracture patients aged > 60 years with available plasma TSH-measurements at admission. Results: Of the 914 included patients (24% men and 76% women), 10.5% died within 30 days. At inclusion, 161 (17.6%) of the patients were hyperthyroid (TSH < 0.65 mIU/L), 58 (6.4%) were hypothyroid (TSH > 4.8 mIU/L), while 695 (76.0%) were euthyroid (0.65 < TSH < 4.80 mIU/L), p = 0.03. Mortality was significantly higher in the two higher quartiles of TSH [Q3 (13.0%) and Q4 (15.4%)] compared to the two lower quartiles [Q1 (7.4%) and Q2 (6.2%), p = 0.0003. After adjustment for age, sex and Charlson Comorbidity Index (CCI) in a Cox proportional hazard model, the risk of 30-day mortality continued to be increased in patients with TSH above the median as compared to patients with TSH below the median (HR 2.1 (1.4–3.3), p = 0.0006]. Conclusion: The study demonstrates increased 30-day mortality in surgically treated hip fracture patients with plasma TSH levels above the median (1.41 mIU/L) at admission, even after adjusting for age, sex and CCI.",
keywords = "Elderly patients, Hip fracture, Mortality, Thyroid-stimulating hormone, TSH",
author = "Etienne Rapacki and Lauritzen, {Jes B.} and Madsen, {Christian M.} and J{\o}rgensen, {Henrik L.} and Debbie Norring-Agerskov",
year = "2021",
doi = "10.1007/s00068-019-01260-9",
language = "English",
volume = "47",
pages = "1081–1087",
journal = "European Journal of Trauma and Emergency Surgery",
issn = "1863-9933",
publisher = "Springer Medizin",

}

RIS

TY - JOUR

T1 - Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients

AU - Rapacki, Etienne

AU - Lauritzen, Jes B.

AU - Madsen, Christian M.

AU - Jørgensen, Henrik L.

AU - Norring-Agerskov, Debbie

PY - 2021

Y1 - 2021

N2 - Purpose: The aim of this study is to assess the possible association between thyroid-stimulating hormone (TSH) and mortality in hip fracture patients. Patients and methods: The study is based on a hip fracture database from Bispebjerg University Hospital (Copenhagen, Denmark). This database includes all hip fracture patients (ICD-10 codes DS720 (femoral neck), DS721 (pertrochanteric), and DS722 (subtrochanteric)) admitted to Bispebjerg Hospital from 1996 to 2012. From this database, we identified all surgically treated hip fracture patients aged > 60 years with available plasma TSH-measurements at admission. Results: Of the 914 included patients (24% men and 76% women), 10.5% died within 30 days. At inclusion, 161 (17.6%) of the patients were hyperthyroid (TSH < 0.65 mIU/L), 58 (6.4%) were hypothyroid (TSH > 4.8 mIU/L), while 695 (76.0%) were euthyroid (0.65 < TSH < 4.80 mIU/L), p = 0.03. Mortality was significantly higher in the two higher quartiles of TSH [Q3 (13.0%) and Q4 (15.4%)] compared to the two lower quartiles [Q1 (7.4%) and Q2 (6.2%), p = 0.0003. After adjustment for age, sex and Charlson Comorbidity Index (CCI) in a Cox proportional hazard model, the risk of 30-day mortality continued to be increased in patients with TSH above the median as compared to patients with TSH below the median (HR 2.1 (1.4–3.3), p = 0.0006]. Conclusion: The study demonstrates increased 30-day mortality in surgically treated hip fracture patients with plasma TSH levels above the median (1.41 mIU/L) at admission, even after adjusting for age, sex and CCI.

AB - Purpose: The aim of this study is to assess the possible association between thyroid-stimulating hormone (TSH) and mortality in hip fracture patients. Patients and methods: The study is based on a hip fracture database from Bispebjerg University Hospital (Copenhagen, Denmark). This database includes all hip fracture patients (ICD-10 codes DS720 (femoral neck), DS721 (pertrochanteric), and DS722 (subtrochanteric)) admitted to Bispebjerg Hospital from 1996 to 2012. From this database, we identified all surgically treated hip fracture patients aged > 60 years with available plasma TSH-measurements at admission. Results: Of the 914 included patients (24% men and 76% women), 10.5% died within 30 days. At inclusion, 161 (17.6%) of the patients were hyperthyroid (TSH < 0.65 mIU/L), 58 (6.4%) were hypothyroid (TSH > 4.8 mIU/L), while 695 (76.0%) were euthyroid (0.65 < TSH < 4.80 mIU/L), p = 0.03. Mortality was significantly higher in the two higher quartiles of TSH [Q3 (13.0%) and Q4 (15.4%)] compared to the two lower quartiles [Q1 (7.4%) and Q2 (6.2%), p = 0.0003. After adjustment for age, sex and Charlson Comorbidity Index (CCI) in a Cox proportional hazard model, the risk of 30-day mortality continued to be increased in patients with TSH above the median as compared to patients with TSH below the median (HR 2.1 (1.4–3.3), p = 0.0006]. Conclusion: The study demonstrates increased 30-day mortality in surgically treated hip fracture patients with plasma TSH levels above the median (1.41 mIU/L) at admission, even after adjusting for age, sex and CCI.

KW - Elderly patients

KW - Hip fracture

KW - Mortality

KW - Thyroid-stimulating hormone

KW - TSH

U2 - 10.1007/s00068-019-01260-9

DO - 10.1007/s00068-019-01260-9

M3 - Journal article

C2 - 31696265

AN - SCOPUS:85074836032

VL - 47

SP - 1081

EP - 1087

JO - European Journal of Trauma and Emergency Surgery

JF - European Journal of Trauma and Emergency Surgery

SN - 1863-9933

ER -

ID: 231641909